346 Results for "

Complement

" in MedChemExpress (MCE) Product Catalog:
Products (346)

346 Results for "Complement" in MCE Product Catalog:

14
14 Publications Verification
Cat. No.: HY-110136
CAS No.: 514814-49-4
Purity:  99.54%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.
loading...
    loading...
14
14 Publications Verification
Cat. No.: HY-110136A
Purity:  99.50%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

PMX 205 Trifluoroacetate is a specific complement C5aR1 isoform antagonist .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-127105
CAS No.: 1644670-37-0
Purity:  99.93%
Synonyms: LNP023
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-127105A
CAS No.: 1646321-63-2
Purity:  99.83%
Synonyms: LNP023 hydrochloride
Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-138161
CAS No.: 2411440-41-8
Purity:  99.59%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-106178
CAS No.: 219639-75-5
Purity:  99.98%
Synonyms: 3D53
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-P7863
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rMuComplement C3/C3a; Complement Component C3a; Anaphylatoxin; C3a
Species:  
Source:  
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P7695
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rMuC5a; Complement C5; Hemolytic Complement; C5a
Species:  
Source:  
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P1717
CAS No.: 1427001-89-5
Synonyms: Cp40
Research Areas:  

Inflammation/Immunology

AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P1717B
Synonyms: Cp40 acetate
Research Areas:  

Inflammation/Immunology

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-P1717A
CAS No.: 1789738-04-0
Synonyms: Cp40 TFA
Research Areas:  

Inflammation/Immunology

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P7862
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuComplement C3/C3a; Complement Component C3a; C3a; Anaphylatoxin
Species:  
Source:  
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-117930
CAS No.: 1903768-17-1
Purity:  99.91%
Synonyms: ACH-4471
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-17627
CAS No.: 1346623-17-3
Synonyms: CCX168
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Avacopan (CCX168) is a potent, selective and orally available complement 5a receptor (C5aR) inhibitor with an IC50 of 0.1 nM.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P990545
CAS No.: 2065212-40-8
Synonyms: ANX005

Target:  

Complement System

Research Areas:  

Neurological Disease

Tanruprubart (ANX005) is a C1q inhibitor and C1q depleter. Tanruprubart is a human antibody expressed in CHO cells, with huIgG1 heavy chains and huκ light chains, and its predicted molecular weight (MW) is 145 kDa. For the isotype control of Tanruprubart, refer to Human IgG4 kappa, Isotype Control (HY-P99003). The IC50 of Tanruprubart is 346 ng/mL for humans and 259 ng/mL for rats; its EC50 is 3.8 ng/mL for humans, 5.2 ng/mL for rats, and 9.9 ng/mL for mice. Tanruprubart is applicable to the research of Guillain-Barré syndrome and Alzheimer's disease .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-148141
CAS No.: 1254036-23-1
Purity:  99.96%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 μM) and reduces TNF levels (EC50=4.5 μM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-116282
CAS No.: 9011-18-1
Purity:  99.20%
Synonyms: DSS (MW 5000); DXS (MW 5000)
Dextran sulfate sodium salt (DSS) (MW 5000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt (DSS) with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 5000) is an inhibitor of complement and coagulation pathways, and belongs to the glycosaminoglycans (GAG) family. Dextran sulfate sodium salt (MW 5000) acts as an anticoagulant, antiviral, and anti-lipemic agent. Dextran sulfate sodium salt (DSS) stops HIV-1 virus adsorption to host cells. Dextran sulfate sodium salt (MW 5000) prevents NK cell-mediated cytotoxicity. Dextran sulfate sodium salt (MW 5000) inhibits instant blood-mediated inflammatory reaction (IBMIR) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P9914
CAS No.: 219685-50-4
Synonyms: Anti-Human C5, Humanized Antibody; h5G1.1
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1036
CAS No.: 206645-99-0
Target:  

Complement System

Research Areas:  

Others

Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1036A
Target:  

Complement System

Research Areas:  

Others

Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively .
loading...
    loading...